this issue:
Association of initial DMT with later conversion to secondary progressive MS
Effect of HSCT vs continued DMT on disease progression in RRMS
BMI but not vitamin D status is associated with brain volume change in MS
Therapeutic responsiveness to fampridine in MS
Rituximab for SPMS and disability progression
Comparison of fingolimod, DMF and teriflunomide for MS
Food allergies are associated with increased disease activity in MS
Alemtuzumab or rituximab after fingolimod withdrawal in RRMS is effective and safe
Factors impacting parenthood decisionmaking in people with MS
Safety and efficacy of helminth treatment in RRMS
Please login below to download this issue (PDF)